Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Lapatinib + MK2206|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Lapatinib||Tykerb||Lapatinib Ditosylate||EGFR Inhibitor (Pan) 46 HER2 (ERBB2) Antibody 38||Tykerb (lapatinib) reversibly inhibits ERBB2 (HER2) and EGFR, resulting in decreased downstream signaling and potentially leading to reduced tumor growth (PMID: 22477724). Tykerb (lapatinib) is FDA approved for ERBB2 (HER2)-positive (overexpressing) breast cancer (FDA.gov).|
|MK2206||MK-2206||Akt Inhibitor (Pan) 18||MK2206 binds to and inhibits the activity of AKT in a non-ATP competitive manner, which may result in the inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation (PMID: 20571069, PMID: 32194695).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 positive||Her2-receptor positive breast cancer||sensitive||Lapatinib + MK2206||Phase I||Actionable||In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198).||27026198|
|Unknown unknown||Advanced Solid Tumor||not applicable||Lapatinib + MK2206||Phase I||Actionable||In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 4 months in 9% (2/23) of patients with advanced solid tumors (PMID: 27026198).||27026198|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|